A Proof-of-Concept Clinical Trial of Intratumoral Injection of GLA-SE, a Toll-like Receptor-4 Agonist, in Patients With Merkel Cell Carcinoma

Trial Profile

A Proof-of-Concept Clinical Trial of Intratumoral Injection of GLA-SE, a Toll-like Receptor-4 Agonist, in Patients With Merkel Cell Carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Glycopyranosyl lipid adjuvant (Primary)
  • Indications Merkel cell carcinoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Immune Design
  • Most Recent Events

    • 08 Jun 2016 According to an Immune design media release, the company announced updated results of this trial and the data was presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) annual meeting.
    • 07 Jun 2016 Results of clinical and immunologic effects on the tumor microenvironment presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 21 Apr 2016 Final results of this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016, according to an Immune design media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top